Olaparib in Treating Patients With Stage IV Pancreatic Cancer
Status:
Active, not recruiting
Trial end date:
2022-11-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well olaparib works in treating patients with stage IV
pancreatic cancer. Olaparib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.